Cytek Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
Cytek Biosciences has a total shareholder equity of $385.5M and total debt of $3.2M, which brings its debt-to-equity ratio to 0.8%. Its total assets and total liabilities are $491.2M and $105.8M respectively.
Key information
0.8%
Debt to equity ratio
US$3.23m
Debt
| Interest coverage ratio | n/a |
| Cash | US$277.78m |
| Equity | US$385.46m |
| Total liabilities | US$105.76m |
| Total assets | US$491.23m |
Recent financial health updates
Is Cytek Biosciences (NASDAQ:CTKB) Weighed On By Its Debt Load?
Dec 16
Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?
Jul 12Recent updates
Is Cytek Biosciences (NASDAQ:CTKB) Weighed On By Its Debt Load?
Dec 16Investors Still Aren't Entirely Convinced By Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Despite 46% Price Jump
Nov 07Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Shares Not Telling The Full Story
Sep 13An Intrinsic Calculation For Cytek Biosciences, Inc. (NASDAQ:CTKB) Suggests It's 49% Undervalued
Aug 09Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?
Jul 12Potential Upside For Cytek Biosciences, Inc. (NASDAQ:CTKB) Not Without Risk
Jun 04Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader
Mar 20Cytek Biosciences' (NASDAQ:CTKB) Solid Profits Have Weak Fundamentals
Mar 08Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments
Jul 27Checking In On Cytek Biosciences
Mar 23Financial Position Analysis
Short Term Liabilities: CTKB's short term assets ($390.2M) exceed its short term liabilities ($62.8M).
Long Term Liabilities: CTKB's short term assets ($390.2M) exceed its long term liabilities ($43.0M).
Debt to Equity History and Analysis
Debt Level: CTKB has more cash than its total debt.
Reducing Debt: Insufficient data to determine if CTKB's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CTKB has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CTKB is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 8.5% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 23:20 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cytek Biosciences, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Mikson | Canaccord Genuity |
| Matthew Sykes | Goldman Sachs |
| Tejas Savant | Morgan Stanley |